Sanofi on Monday sued Mylan, accusing the pharmaceutical company of engaging in illegal conduct to squelch competition to its EpiPen allergy treatment » Read More
By: Ed Lane
Samsung Bioepis has won regulatory approval for key biosimilar drug, the first time the company's product has been approved for U.S. use. » Read More
By: Meg Tirrell
This Saturday's March for Science is trying hard to be a nonpartisan event, but some may not see it that way. » Read More
The Fast Money traders discuss whether the pharmaceutical company will be acquired.
Shares of Walgreen Boots Alliance and Rite Aid are trading lower after the merger of the two drugstore companies is facing US antitrust concerns.
The lung cancer treatment is still expected to receive approval in the second half of 2018.
Have allergies? This EpiPen rival has a list price of $4,500, but most patients won't pay a cent.
Mallinckrodt has agreed to pay $100 million to settle allegations that it broke U.S. antitrust law by sharply increasing the price of a multiple sclerosis drug.
Mallinkrodt was being investigated in connection with big price increases for its drug Achthar Gel.
Merck Group CEO Stefan Oschmann discusses his outlook for 2017 and how big data is transforming the pharmaceuticals industry.
Novartis CEO Joe Jimenez discusses investment in the United States under U.S. President-elect Donald Trump.
Merck Group CEO Stefan Oschmann speaks about how his world has changed after Donald Trump's election.
Novartis CEO Joe Jimenez discusses how his sector may develop under Donald Trump's presidency.
Steve Brozak at WBB Securities explains why he favors Omeros stocks.
The lack of clarity over Trump’s policies was so great that fund manager Invesco is reducing risk exposure, a senior portfolio manager said.
The new CMS classification means the device is eligible for Medicaid and Medicare coverage.
It's becoming obvious Big Pharma's iron wall of protection in Washington is starting to crumble, says Jake Novak.
Price and Rep. Chris Collins, R-N.Y., got a 12 percent discount in their private placement purchase of stock in an Australian drug company.
"Sugar Goggles," a virtual reality game, is hoping to encourage children to make healthier eating choices and adjust eating habits.
When someone goes into opioid overdose, their body begins shutting down. But there’s a drug that can stop the process. Naloxone has saved the thousands of people after they overdosed. Here’s how it works.
Investor optimism regarding the outlook for European healthcare stocks continued to decline dramatically on Thursday.
Morgan Stanley's 2020 earnings-per-share estimate for Merck is $5.82 versus the Wall Street consensus of $4.97.
Andrew Keene at KeeneOnTheMarket.com says that Trump is still better for pharmaceutical stocks than Clinton would have been.
Get the best of CNBC in your inbox